Nectin Therapeutics collaborates with Merck on clinical trial of NTX1088 with KEYTRUDA®

Nectin Therapeutics, a Peregrine Ventures portfolio company, entered into a clinical trial collaboration with Merck to evaluate NTX1088 in combination with KEYTRUDA® (pembrolizumab) in patients with locally advanced and metastatic solid tumors.
NTX1088 is Nectin’s first-in-class monoclonal antibody targeting PVR (CD155), an immune checkpoint associated with resistance to PD-1 and PD-L1 therapies. The Phase 1 study evaluates the safety, tolerability and antitumor activity of NTX1088, both as a monotherapy and in combination with KEYTRUDA®.

Official announcement: Nectin Therapeutics